Overall, there was no significant association between IL-12B rs3212227 polymorphism and cervical cancer risk under all five genetic models genetic models, i.e., allele (C vs. A: OR = 1.076, 95% CI 0.783-1.479, p=0.651, Figure 2A), homozygote (CC vs. AA: OR = 1.330, 95% CI 0.988-1.790, p=0.060), heterozygote (CA vs. AA: OR = 1.119, 95% CI 0.696-1.800, p=0.643), dominant (CC+CA vs. AA: OR = 1.125, 95% CI 0.704-1.799, p =0.623, Fig2B), recessive (CC vs. CA+AA: OR = 1.140, 95% CI 0.874-1.487, p =0.333). This evidence concerns the gene IL12B and cervical cancer.